The Food and Drug Administration on Thursday approved Trulicity (dulaglutide), a once-a-week injection to improve blood-sugar levels in adults with Type 2 diabetes.
The Generic Pharmaceutical Association on Thursday provided input on the Generic Drug User Fee Act process before the Food and Drug Administration.
Mission Pharmacal on Tuesday participated in a White House Industry Leadership Roundtable discussion on ways to curb emissions of hydrofluorocarbons.
The Ohio governor's office pushed for the firing of the executive director of the Ohio State Board of Pharmacy, according to a report released by the Associated Press Tuesday.
With diabetes and other diseases at epidemic levels, the need for more pharmacies to step up and offer accessible, convenient patient screening for a variety of serious and even life-threatening conditions is clear, a panel of pharmacists asserted at the NACDS Total Store Expo “Convenient Care — Point of Care Testing in the Pharmacy” Insight Session in late August. So, too, is the opportunity to drive new business to the pharmacy through point-of-care testing services.
The Food and Drug Administration on Tuesday announced approval for Movantik (naloxegol), a treatment for opioid-induced constipation in adults.
Baxter International announced that the Food and Drug Adminsitration approved Rixubis [coagulation factor IX (recombinant)] for the treatment, control and prevention of bleeding episodes, as well as perioperative management, in children with hemophilia B.
The Council for Responsible Nutrition on Monday praised the U.S. House of Representatives for its passage of the Designer Anabolic Steroid Control Act of 2014 (H.R. 4771), introduced by Reps. Joe Pitts, R-Pa., and Frank Pallone, D-N.J.
Thanks to the Centers for Medicare and Medicaid Services’ Five-Star Quality Rating System, the diabetes community stands to play a significant role in how pharmacies think about their patients and their medication adherence programs.
The Department of Justice announced Friday that it filed a motion to hold Bayer in civil contempt for violating a court order in the U.S. District Court for the District of New Jersey.